These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Angiotensin-induced release of prostacyclin from perfused organs. Grodzińska L; Gryglewski RJ Pharmacol Res Commun; 1980 Apr; 12(4):339-47. PubMed ID: 6994129 [No Abstract] [Full Text] [Related]
28. Role of endothelium-derived bradykinin in the control of vascular tone. Hecker M; Dambacher T; Busse R J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S55-61. PubMed ID: 1282631 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the release of vasoactive factors from venous and arterial bovine cultured endothelial cells. D'Orleans-Juste P; Mitchell JA; Wood EG; Hecker M; Vane JR Can J Physiol Pharmacol; 1992 May; 70(5):687-94. PubMed ID: 1423010 [TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of agonist-induced but not shear stress-dependent release of endothelial autacoids by thapsigargin. Macarthur H; Hecker M; Busse R; Vane JR Br J Pharmacol; 1993 Jan; 108(1):100-5. PubMed ID: 8428199 [TBL] [Abstract][Full Text] [Related]
31. Methylene blue but not changes in cyclic GMP inhibits resting and bradykinin-stimulated production of prostacyclin by pig aortic endothelial cells. Martin W; Drazan KM; Newby AC Br J Pharmacol; 1989 May; 97(1):51-6. PubMed ID: 2541859 [TBL] [Abstract][Full Text] [Related]
32. Endothelium-derived relaxing factor and atriopeptin II elevate cyclic GMP levels in pig aortic endothelial cells. Martin W; White DG; Henderson AH Br J Pharmacol; 1988 Jan; 93(1):229-39. PubMed ID: 2894877 [TBL] [Abstract][Full Text] [Related]
33. Endothelial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells. Kuhn M; Otten A; Frölich JC; Förstermann U J Pharmacol Exp Ther; 1991 Feb; 256(2):677-82. PubMed ID: 1847208 [TBL] [Abstract][Full Text] [Related]
34. Prostacyclin mediates the potentiated hypotensive effect of bradykinin following captopril treatment. Mullane KM; Moncada S Eur J Pharmacol; 1980 Sep; 66(4):355-65. PubMed ID: 6998710 [TBL] [Abstract][Full Text] [Related]
35. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Radomski MW; Palmer RM; Moncada S Br J Pharmacol; 1987 Nov; 92(3):639-46. PubMed ID: 3322462 [TBL] [Abstract][Full Text] [Related]
36. Pericardial release of prostacyclin induced by bradykinin and angiotensin II: effects on coronary blood flow in the dog. Woodman OL; Dusting GJ; Nolan RD J Cardiovasc Pharmacol; 1983; 5(6):954-60. PubMed ID: 6196567 [TBL] [Abstract][Full Text] [Related]
37. Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery. Miyamoto A; Murata S; Nishio A Naunyn Schmiedebergs Arch Pharmacol; 2002 May; 365(5):365-70. PubMed ID: 12012022 [TBL] [Abstract][Full Text] [Related]
38. Potentiation of the vasorelaxant activity of nitric oxide by hydroxyguanidine: implications for the nature of endothelium-derived relaxing factor. Zembowicz A; Swierkosz TA; Southan GJ; Hecker M; Vane JR Br J Pharmacol; 1992 Dec; 107(4):1001-7. PubMed ID: 1281716 [TBL] [Abstract][Full Text] [Related]
39. Endothelium-derived relaxing factor is a selective relaxant of vascular smooth muscle. Shikano K; Berkowitz BA J Pharmacol Exp Ther; 1987 Oct; 243(1):55-60. PubMed ID: 3499504 [TBL] [Abstract][Full Text] [Related]
40. Effect of SKF 525A on the release of nitric oxide and prostacyclin from endothelial cells. Rees DD; Palmer RM; Moncada S Eur J Pharmacol; 1988 May; 150(1-2):149-54. PubMed ID: 3136027 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]